Novartis launches first targeted combination treatment for advanced melanoma in the UK, but immediate access for patients uncertain

Novartis has announced that Tafinlar® (dabrafenib) + Mekinist® (trametinib), the first oral targeted combination therapy to be licensed for advanced melanoma, is now available in the UK...